NeuroDerm Ltd. (NASDAQ:NDRM) saw an uptick in trading volume on Monday . 69,348 shares changed hands during mid-day trading, a decline of 6% from the previous session’s volume of 73,963 shares.The stock last traded at $17.16 and had previously closed at $17.04.

Several brokerages recently issued reports on NDRM. Roth Capital restated a “buy” rating on shares of NeuroDerm in a report on Sunday, May 29th. Oppenheimer Holdings Inc. began coverage on shares of NeuroDerm in a report on Saturday, April 2nd. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $24.70.

The stock has a 50 day moving average price of $17.02 and a 200 day moving average price of $15.33. The firm’s market cap is $374.05 million.

NeuroDerm (NASDAQ:NDRM) last announced its quarterly earnings results on Thursday, May 26th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10. Equities research analysts anticipate that NeuroDerm Ltd. will post ($1.52) EPS for the current fiscal year.

NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease; ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson’s disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.